China NMPA Medical Device Registration: Agent, Type Testing, Clinical Evaluation and Timelines

China is the second-largest medical device market in the world, and it is the one that most surprises teams used to reusing FDA or CE evidence. The National Medical Products Administration (NMPA) does not accept a foreign approval as a substitute for its own review, and the project usually includes a China agent, testing in China and a defined clinical evaluation. This guide explains the registration system step by step so that you can scope the work, the schedule and the budget before you start.

The legal framework

Medical devices in China are regulated under the Regulations for the Supervision and Administration of Medical Devices (State Council Order 739), in force since 1 June 2021, together with implementing rules such as the Administrative Measures for Medical Device Registration and Filing. The regulations introduced the Medical Device Registrant and Filer system. The registrant, which for an imported device is the overseas manufacturer, holds the registration and carries responsibility for the whole life cycle of the device, including quality, post-market surveillance and adverse event reporting.

Classification and route

Class	Risk	Route	Who reviews an imported device
I	Low	Filing (record)	NMPA
II	Moderate	Registration	NMPA, with technical review by the Center for Medical Device Evaluation (CMDE)
III	High	Registration	NMPA, with technical review by CMDE

China publishes a classification catalogue and classification rules. Always check the catalogue entry for your product first, because a device that you consider Class II can be placed in Class III, and a reclassification late in the project means starting evidence work again. Our overview of device classification explains how to document your logic, and the same record helps in a Chinese classification enquiry.

The registration steps for an imported device

1. Confirm classification and the device category. Use the catalogue and, if needed, request a classification opinion.
2. Appoint a China agent. An overseas manufacturer must designate an enterprise in China to act as its agent and domestic responsible party. The agent submits documents, communicates with NMPA, supports post-market duties and holds legal accountability in China.
3. Write the Product Technical Requirements (PTR). The PTR is a Chinese-language document that defines the performance and safety specifications of the device and the test methods, and it becomes the basis of type testing and of later inspections.
4. Complete type testing. For most Class II and III devices, samples are tested at a qualified testing institute in China against the PTR and applicable national or industry standards. This covers electrical safety and EMC where relevant, performance, and biological evaluation to the Chinese version of ISO 10993.
5. Prepare the clinical evaluation. Depending on the device, the route is an exemption listed in a catalogue of devices exempt from clinical evaluation, a comparison with an equivalent device already registered in China, or a clinical trial. Foreign clinical data can be accepted under defined conditions, but it is assessed case by case and may need to demonstrate relevance to Chinese patients.
6. Compile the registration dossier. It includes the application, product risk management, technical documentation, PTR, test reports, clinical evaluation, labels and instructions in Chinese, and the quality system information. For an imported device, you also provide documents showing the manufacturer’s legal marketing status in its home country, or an explanation where no approval is required there.
7. Submit, respond to questions and receive the certificate. CMDE reviews the technical content and may issue supplementary requests. A quality system verification, which can include an inspection of the manufacturing site, may form part of the review.

Type testing and the PTR in practice

Testing in China is the step that most often surprises foreign companies. Existing test reports from other countries do not automatically replace it. They are still valuable, because they show where your device is likely to pass and they feed the PTR. Practical advice:

• Write the PTR with engineering input and check that every method can be performed by a Chinese lab.
• Ship samples early, with the required accessories and software versions, and plan for the lab queue.
• Freeze the design that will be tested. A design change after testing can mean repeating tests, so align the testing plan with your change control process.
• For active devices, align with the Chinese versions of the standards behind IEC 60601 safety and EMC.

Clinical evaluation strategy

Clinical evidence is the main driver of cost and time for Class III devices. Start by checking whether the device qualifies for the exemption catalogue or for an equivalence argument. If a trial is needed, decide whether a multi-regional study can serve several markets. Data from an IDE study or other ISO 14155 trial may support the file, but you should confirm early with your China agent or NMPA whether the population, endpoints and follow-up will be accepted.

Timelines, validity and costs

Sources vary, so treat these figures as planning ranges rather than promises:

• Class I filing: usually weeks, as it is an administrative filing.
• Class II registration: commonly one to two years from preparation to certificate, including testing.
• Class III registration: commonly one-and-a-half to three years or more, and longer where a Chinese clinical trial is required.

Government review fees are published and are charged per application, while the larger costs are testing, translation, the agent, and clinical work. A registration certificate is valid for five years, and a renewal application is due about six months before expiry. Changes affecting safety or effectiveness need a change registration, and smaller changes are filed or notified.

After registration

• Quality system. The registrant maintains a quality management system that meets Chinese requirements and is open to inspection.
• Adverse events and PMS. The registrant and agent must monitor and report adverse events, run post-market activities and support recalls. Connect these to your post-market surveillance and recall processes.
• UDI. China is phasing in unique device identification by class. High-risk devices and a set of Class II devices are already covered, and further classes follow on a published timetable. Read how identification works in the US and EU in our UDI guide, and check the current Chinese schedule.
• Labels in Chinese. Chinese labelling is controlled and must be consistent with the registered instructions.
• Commercial context. Volume-based procurement programmes and hospital tenders have reduced prices in several device categories, so build market pricing into the business case.

Choosing the right agent and structure

The agent matters because it files your documents, holds local liability and handles questions from the regulator. Options include an independent regulatory services company, a distributor, or your own Chinese subsidiary. Weigh independence from a single distributor against convenience, and check how the contract handles document ownership, change of distributor and termination, so that you do not lose control of your registration data.

Common mistakes

• Expecting FDA or CE approval to shorten the process without checking what NMPA will accept.
• Starting testing before the PTR and design are stable.
• Underestimating the clinical evaluation work for Class III devices.
• Letting a distributor control the registration without a clear contract.
• Treating translation as a last step. The PTR, labels and instructions all need accurate Chinese versions.
• Missing the renewal window or change notifications after launch.

Frequently asked questions

Can a foreign manufacturer register a device in China directly?

An overseas manufacturer is the registrant, but it must appoint an agent in China to submit documents and carry local responsibility. The agent does not replace the manufacturer’s own duties.

Is testing in China always required?

For most Class II and III devices, type testing at a qualified Chinese institute is part of registration. Foreign test reports help prepare, but they do not usually replace it.

Are Chinese clinical trials always needed?

No. Some devices qualify for an exemption catalogue or an equivalence route, and foreign data can be accepted in defined cases. Higher-risk and novel devices are more likely to need local clinical evidence.

How long is a registration valid?

Registration certificates are valid for five years, and renewal should be filed well before expiry. Class I filings do not expire but must be updated when information changes.

China’s rules, catalogues and timetables are updated regularly. This guide reflects public information available in November 2026 and is for training purposes. Confirm current requirements with NMPA, your China agent and your regulatory advisers.

Related reading

• Global market access beyond the US and EU: how China compares with other markets.
• Regulatory strategy for US and EU market entry: a method you can extend to Asia.
• Biocompatibility (ISO 10993): the evaluation behind Chinese biological testing.
• UDI in the EU and US: how identification systems work.
• RAC (Devices) study material: covers NMPA and other global systems.

Talk to the AptSkill team

Scoping a China registration or building skills in global regulatory affairs? Send us your device type, target markets and goal.